Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Brown University
Memorial Sloan Kettering Cancer Center
Genentech, Inc.
UroGen Pharma Ltd.
M.D. Anderson Cancer Center
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Toray Industries, Inc
Trishula Therapeutics, Inc.
Baylor College of Medicine
Trishula Therapeutics, Inc.
First Affiliated Hospital of Chongqing Medical University
Eli Lilly and Company
Emory University
University of California, Davis
Gossamer Bio Inc.
H. Lee Moffitt Cancer Center and Research Institute
Masonic Cancer Center, University of Minnesota
Northwestern University
Mayo Clinic
Altor BioScience
Memorial Sloan Kettering Cancer Center
European Organisation for Research and Treatment of Cancer - EORTC
University of Pittsburgh
Dartmouth-Hitchcock Medical Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center